Click here for slides on this topic


Abciximab

An oral antiplatelet agent of the glycoproetin (Gp) IIb/IIIa inhibitor class.


The following content matched the glossary term: Abciximab

Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial)

Top

Stuckey TD, Stone GW, Cox DA, et al. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). Am J Cardiol.. 2005;95:1-7. We sought to determine the benefits of stent implantation and abciximab in patients with diabetes mellitus and acute myocardial infarction (AMI) who underwent primary angioplasty. In a 2-by-2 factorial design, 2,082 patients with AMI were randomly assigned to balloon angioplasty versus stenting, with or without abciximab. 

Outcome of Acute ST-Segment Elevation Myocardial Infarction in Diabetics Treated w Fibrinolytic or Combination Reduced Fibrinolytic Therapy & Glycoprotein

Top

Gurm HS, MD, Lincoff AM, MD, Lee D, MD, et al. Outcome of Acute ST-Segment Elevation Myocardial Infarction in Diabetics Treated With Fibrinolytic or Combination Reduced Fibrinolytic Therapy and Platelet Glycoprotein IIb/IIIa Inhibition. Lessons From the GUSTO V Trial. J Am Coll Cardiol. 2004;43:542-548. We studied the outcome of diabetics enrolled in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) V trial to assess whether the combination of half-dose reteplase and abciximab provides any propitious benefits over standard fibrinolytic therapy in diabetic patients.



Slide Library Results

Search Results for: Abciximab Slides Found: 0